Oral MEK 1/2 Inhibitor Trametinib in Combination With AKT Inhibitor GSK2141795 in Patients With Acute Myeloid Leukemia With RAS Mutations: A Phase II Study
Brittany Knick Ragon(The University of Texas MD Anderson Cancer Center), Nitin Jain(Parul University), Marina Konopleva(Albert Einstein College of Medicine), Loren Joseph(University of Chicago), Helen Ma(Columbia University Irving Medical Center), Maria R. Baer(University of Maryland, Baltimore), Helen Chen(IQVIA (United States)), Gautam Borthakur(The University of Texas MD Anderson Cancer Center), Olatoyosi Odenike(University of Chicago), Yang Zhao(The University of Texas MD Anderson Cancer Center), Lina Han(Hebei Medical University), Wendy Stock(University of Chicago), Keith Baggerly(The University of Texas MD Anderson Cancer Center), Keyur P. Patel(The University of Texas MD Anderson Cancer Center)
Cited by 67
Related Papers
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k
KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study
|The Lancet|2021|795
<i>TP53</i> and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes
|New England Journal of Medicine|2016|783
<i>IDH1</i> and <i>IDH2</i> Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study
|Journal of Clinical Oncology|2010|764
The genomic landscape of hypodiploid acute lymphoblastic leukemia
|Nature Genetics|2013|737